Alan Barnicle

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira et al. · Clinical Cancer Research · 2020 · 107 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial

Joaquı́n Mateo, Johann S. de Bono, Karim Fizazi et al. · Journal of Clinical Oncology · 2023 · 91 citations · Full text

Medicine, Oncology, Pharmacology +16

Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N., Alan Barnicle, Caroline Sibilla et al. · Clinical Cancer Research · 2022 · 71 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

Éric Pujade-Lauraine, Jessica Brown, Alan Barnicle et al. · JCO Precision Oncology · 2023 · 58 citations · Full text

Life Sciences, Genetics, Oncology +17

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Andrés Poveda, Stéphanie Lheureux, Nicoletta Colombo et al. · Gynecologic Oncology · 2022 · 57 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17